Skip to main content

ATAI Life Sciences N.V. (ATAI)

NASDAQ: ATAI · IEX Real-Time Price · USD
14.02
-0.10 (-0.71%)
After-hours:Oct 25, 2021 7:29 PM EDT
14.12
-1.13 (-7.41%)
At close: Oct 25, 4:00 PM
Market Cap2.16B
Revenue (ttm)19.88M
Net Income (ttm)n/a
Shares Out154.82M
EPS (ttm)-8.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume554,498
Open15.34
Previous Close15.25
Day's Range13.70 - 15.39
52-Week Range12.12 - 22.91
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 16, 2021

About ATAI

ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. It is expected that more than 50% of the U.S. population will be diagnosed with a mental health disorder at some point in their lifetime, with increasing incidence ascribed to the COVID-19 pandemic. We founded atai Life Sciences in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooke...

IndustryBiotechnology
IPO DateJun 18, 2021
CEOFlorian Brand
Employees35
Stock ExchangeNASDAQ
Ticker SymbolATAI
Full Company Profile

Financial Performance

Financial Statements

News

atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health App...

atai Impact is committed to advancing education, expanding access and supporting the wider ecosystem of mental health care atai Impact is committed to advancing education, expanding access and supportin...

6 days ago - GlobeNewsWire

What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health Disorders

Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix. PsyProtix is a precision psychiatry company focused on devel...

2 weeks ago - Benzinga

Atai Life Launches Depression-Focused Firm

Atai Life Sciences NV (NASDAQ: ATAI) has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout.  PsyProtix is a precision psychiatry company focused ...

2 weeks ago - Benzinga

atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx's Graduation to Toronto Stock Exchange A...

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today an...

1 month ago - GlobeNewsWire

Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine

Perception Neuroscience, an Atai Life Sciences (NASDAQ:ATAI) subsidiary, is starting a Phase 2a clinical trial on PCN-101, its lead drug candidate. The study will evaluate the safety and efficacy of a p...

1 month ago - Benzinga

Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression

NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neurops...

1 month ago - GlobeNewsWire

atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receivi...

BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences  (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disord...

1 month ago - GlobeNewsWire

atai Life Sciences to Participate in Upcoming September Investor Conferences

BERLIN, Sept. 03, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today...

1 month ago - GlobeNewsWire

Atai shares pop after earnings: Company's CEO talks about mental health and psychedelics

Atai Life Sciences, a biopharmaceutical and psychedelic company reported its first earnings since going public in June. Florian Brand, Atai's CEO and co-founder joins Closing Bell to discuss the future ...

2 months ago - CNBC Television

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update

-Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters' over-allotment-

2 months ago - GlobeNewsWire

3 Disruptive Mental Health Stocks to Consider Buying Before They're Huge

They're the first pioneers in exciting new markets.

Other symbols:CMPSTALK
2 months ago - The Motley Fool

atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions

BERLIN, Aug. 12, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences  (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced ...

2 months ago - GlobeNewsWire

Atai Life Sciences To Research Potent Psychedelic Herb Salvia Divinorum Through Its New Subsidiary

Atai Life Sciences (NASDAQ:ATAI) has announced the launch of a new subsidiary that will research Salvinorin A, the active compound in salvia divinorum, a hallucinogenic herb native to Central America. A...

2 months ago - Benzinga

atai Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide B...

BERLIN, Aug. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today ...

2 months ago - GlobeNewsWire

atai Life Sciences to Present at the 41st Annual Canaccord Genuity Growth Conference

BERLIN, Aug. 06, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today ...

2 months ago - GlobeNewsWire

Atai Launches New "Nose-To-Brain" Drug Delivery Company To Interact With Its Portfolio Of Psychedelics Subsidiaries

Atai Life Sciences (NASDAQ:ATAI) is launching a new company that will interact with its portfolio of psychedelics and tech start-ups looking at novel mental health treatments. InnarisBio Inc., as the co...

2 months ago - Benzinga

atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a m...

BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatmen...

2 months ago - GlobeNewsWire

Investment Banks Bullish On Psychedelics Co Atai Life Sciences: Cantor, Credit Suisse, Citigroup, Cowen, Aegis And Ot...

This week, a number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ:ATAI), the Peter Thiel-backed biotech exploring a host of psychedelic compounds and treatment...

3 months ago - Benzinga

Leading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million Raised to Tackle the Growing Global Menta...

CHICAGO, July 15, 2021 /PRNewswire/ --  P alo Santo , the leading U.S.-based psychedelic investment fund, announced its launch with an initial $35 million in capital raised and an active portfolio of 20...

3 months ago - PRNewsWire

Chewy, Brinker, Cleveland-Cliffs, Nvidia and More Thursday Afternoon Analyst Calls

With the trading day more than halfway over, the broad markets saw a loss across the board.

3 months ago - 24/7 Wall Street

atai Life Sciences to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

BERLIN, Germany, July 07, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for va...

3 months ago - GlobeNewsWire

Got $1,000? Consider This Freshly IPO'd Psychedelic Biotech

It's off to a running start.

3 months ago - The Motley Fool

5 Stocks With High Insider Interest

Unique insider buys at high levels through the second quarter

Other symbols:MLVFMPBPHX
3 months ago - GuruFocus

Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public

Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelic space, had its Nasdaq debut on Friday. The Berlin-based company is joining an exclusive group of start-ups in the psychedelics sect...

4 months ago - Benzinga

Peter Thiel-backed psychedelic start-up's shares pop in Wall Street debut

The German biotech's initial public offering was priced Thursday night at $15 per share, the high end of the expected range.

4 months ago - CNBC